Curiously, CD8+ T cells infiltrated ovarian tumors have high TIGIT expression as shown in this paper (Fig. 5), which may suggest ovarian tumors are a potential target for combination anti-LAG3 and anti-TIGIT therapy. This evidence concerns the gene CD8A and ovarian neoplasm.